Delving into the Latest Updates on AT-193 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

AHR

Mechanism

AHR agonists(Aryl hydrocarbon receptor agonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesSkin and Musculoskeletal Diseases+ [1]

Active Indication

Plaque psoriasisPsoriasis of nailHidradenitis Suppurativa

Inactive Indication-

Originator Organization

Azora Therapeutics, Inc.Startup

Active Organization

Azora Therapeutics Australia Pty Ltd

Azora Therapeutics, Inc.Startup

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Part 1 is a randomized, double-blind, placebo-controlled phase 1b study to evaluate AT193 in approximately 34 patients with nail psoriasis for 16 weeks. Part 2 is an open-label extension phase where all patients will receive active drug for an additional 16 weeks followed by a 2 week nontreatment period.

Start Date01 Apr 2022

Sponsor / Collaborator

Azora Therapeutics Australia Pty Ltd

NCT04989517 / CompletedPhase 1

A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of AT193 in the Treatment of Patients With Hidradenitis Suppurativa

This is a randomized, double-blind, placebo-controlled, parallel-group phase 1b study to evaluate AT193 in approximately 44 participants with HS. The treatment period will be 8 weeks followed by a 2-week nontreatment follow-up. The primary objective of this study is to evaluate the safety and tolerability of AT193. The secondary objectives of this study are to evaluate the preliminary efficacy in the treatment of HS.

Start Date23 Nov 2021

Sponsor / Collaborator

Azora Therapeutics Australia Pty Ltd

100 Clinical Results associated with AT-193

Login to view more data

100 Translational Medicine associated with AT-193

Login to view more data

100 Patents (Medical) associated with AT-193

Login to view more data

100 Deals associated with AT-193

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Plaque psoriasis	Phase 1	AU	Azora Therapeutics Australia Pty Ltd	01 Dec 2021
Psoriasis of nail	Phase 1	AU	Azora Therapeutics Australia Pty Ltd	01 Dec 2021
Hidradenitis Suppurativa	Phase 1	AU	Azora Therapeutics Australia Pty Ltd	23 Nov 2021